Form 4: Ultragenyx Accounting Officer Sells Shares for Tax Withholding

Ultragenyx Pharmaceutical Inc.'s SVP, Chief Accounting Officer, Theodore Alan Huizenga, sold 84 shares of common stock to cover tax obligations related to RSU vesting.

Summary

• Theodore Alan Huizenga, SVP, Chief Accounting Officer of Ultragenyx Pharmaceutical Inc. (RARE), reported a transaction on September 5, 2025.
• The transaction involved the sale of 84 shares of common stock at a price of $31.39 per share.
• The sale was conducted to pay required tax withholdings due to the vesting of Restricted Stock Units (RSUs).
• Following this transaction, Mr. Huizenga beneficially owns 50,306 shares of common stock.
• The reported beneficial ownership includes 266 shares acquired under the Company's A&R 2014 Employee Stock Purchase Plan on April 30, 2025.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale.
• Beneficial ownership also includes previously reported shares of common stock underlying RSUs, which are subject to certain vesting conditions.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transaction is a routine insider sale for tax purposes following RSU vesting, which is a common occurrence and does not indicate a positive or negative outlook on the company's performance.

Positives

• The sale was a result of the vesting of Restricted Stock Units (RSUs), which represents compensation earned by the reporting person.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned and non-discretionary sale, which can mitigate concerns about opportunistic insider trading.

Negatives

• The reporting person's direct beneficial ownership of common stock decreased by 84 shares as a result of the sale.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction for a publicly traded biotechnology company. Sales of shares by executives to cover tax obligations upon RSU vesting are common across all industries and typically do not reflect a change in management's outlook on the company's prospects.

Stakeholder Impact

• Shareholders: The sale of 84 shares by a senior executive is a very small transaction relative to the company's total outstanding shares and is unlikely to have any material impact on the share price or shareholder value.
• Employees: The vesting of RSUs and subsequent tax-related sale is a standard part of executive compensation, reflecting the company's compensation practices.

Key Dates

Keywords

Ultragenyx Pharmaceutical, RARE, Form 4, Insider Trading, Theodore Alan Huizenga, SVP Chief Accounting Officer, Stock Sale, RSU Vesting, Tax Withholding, 10b5-1 Plan